您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Hydroxyurea
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Hydroxyurea
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Hydroxyurea图片
CAS NO:127-07-1
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
1g电议
5g电议

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt76.05
Cas No.127-07-1
FormulaCH4N2O2
Solubilityinsoluble in EtOH; ≥21.13 mg/mL in H2O with ultrasonic; ≥3.7 mg/mL in DMSO
Chemical Namehydroxyurea
Canonical SMILESC(=O)(N)NO
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Hydroxyurea is an inhibitor of ribonucleoside diphosphate reductase with IC40, IC70 and IC90 values of 1.5 × 10-3M, 3 × 10-3M, and 10-2M, respectively [1].

Ribonucleoside diphosphate reductase is the rate-limiting enzyme responsible for the conversion of ribonucleotides to deoxyribonucleotides which are essential for DNA synthesis. Thus, inhibition of the enzyme has cellular division arrested in the S phase [2].

In activated peripheral blood mononuclear cells (PBMCs), Hydroxyurea inhibited HIV-1 replication with IC90 value of 0.4 mM [2]. In erythroid cells obtained from β-thalassemia/hemoglobin E (β-Thal/HbE) patients, treatment of 30 μM Hydroxyurea for 96 h significantly increased the fractional fetal hemoglobin (HbF) content [3].

In a mouse xenograft model with SW620 tumors, mice received the combination treatment of Ganciclovir (100 mg/kg, i.p.) and Hydroxyurea (1500 mg/kg, i.p.) for 5 consecutive days showed greater delay on tumor growth compared with Ganciclovir treatment alone, with many of the tumors actually decreasing below their initial sizes. Compared with Ganciclovir treatment alone, addition of Hydroxyurea resulted in increased DNA synthesis inhibition and delayed progression through S phase following removal of drug [4].

References:

[1]. Krakoff I H, Brown N C, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Research, 1968, 28(8): 1559-1565.

[2]. Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clinical Infectious Diseases, 2000, 30(2): S193-S197.

[3]. Watanapokasin Y, Chuncharunee S, Sanmund D, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Gene therapy, 2002, 9(15): 1023-1030.

[4]. Boucher P D, Ostruszka L J, Murphy P J, et al. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene therapy, 2002, 9(15): 1023-1030.

试验操作

Cell experiment:[1]

Cell lines

Erythroid cells

Reaction Conditions

30 μM hydroxyurea for 96 h incubation

Applications

In erythroid cells obtained from β-thalassemia/hemoglobin E (β-Thal/HbE) patients, treatment of 30 μM hydroxyurea for 96 h significantly increased the fractional fetal hemoglobin (HbF) content.

Animal experiment:[2]

Animal models

A mouse xenograft model with SW620 tumors

Dosage form

1500 mg/kg

Once daily by intraperitoneal route (i.p.) for 5 days

Applications

In a mouse xenograft model with SW620 tumors, mice received the combination treatment of ganciclovir (100 mg/kg, i.p.) and hydroxyurea (1500 mg/kg, i.p.) for 5 consecutive days showed greater delay on tumor growth compared with ganciclovir treatment alone, with many of the tumors actually decreasing below their initial sizes.

Note

The technical data provided above is for reference only.

References:

1. Watanapokasin Y, Chuncharunee S, Sanmund D, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Experimental Hematology, 2005, 33(12): 1486-1492.

2. Boucher P D, Ostruszka L J, Murphy P J, et al. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene therapy, 2002, 9(15): 1023-1030.